- BioCure Technology (CURE) has appointed a new president, a Capital Markets Advisor and granted stock options
- Björn Cochlovius, Ph.D. has joined BioCure Technology Inc. as President
- Diverse Capital Pte Ltd. has been appointed as a Capital Markets Advisor
- Biocure is a leading biotech company developing its CAR-T cell therapy for leukemia, lung, breast and pancreatic cancer
- Biocure Technology Inc. (CURE) is unchanged, trading at C$0.20 per share
BioCure Technology (CURE) has appointed a new president, a Capital Markets Advisor and granted stock options to directors, employees and consultants.
Björn Cochlovius, Ph.D. has joined BioCure Technology Inc. as President. Dr. Cochlovius brings leadership experience in multiple management and board positions. He has experience in science, development and fundraising. Dr. Cochlovius is a passionate healthcare professional combining strategic vision and business acumen with a strong scientific and product development background.
Bjoern Cochlovius, Ph.D. is a Molecular Biologist and Associate Professor for Immunology at Heidelberg University, Heidelberg, Germany. His academic career focused on Tumor Immunology and Recombinant Antibodies. He has been Guest Scientist at Zelig Eshhar’s lab at the Weizmann Institute, a pioneer of CAR-T cell technology.
Diverse Capital Pte Ltd. has been appointed as a Capital Markets Advisor.
Diverse Capital was founded by Mr. Steven Pearce, who has over 20 years of experience in the Stock Brokerage, Fund Management and Capital Markets industries.
BioCure Technology Inc. has granted an aggregate of 1,250,000 stock options to certain directors, officers, employees and consultants of the company. The options are exercisable at a price of $0.30 per share for a period of up to 36 months. The options and underlying common shares are subject to a four-month hold period in accordance with the policies of the Canadian Securities Exchange.
Biocure is a leading biotech company developing its CAR-T cell therapy for leukemia, lung, breast and pancreatic cancer.
Biocure Technology Inc. (CURE) is unchanged, trading at C$0.20 per share.
